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cense. httpAbstract Background: Hepatocelluar carcinoma (HCC) is a common cancer worldwide as well as
in Egypt with hepatitis B and C, alcohol and aﬂatoxins being the commonest risk factors. Tamox-
ifen was initially reported to confer a marginal survival beneﬁt in advanced HCC. However, later
reports declined any beneﬁt.
Objective: To study the impact of tamoxifen on overall survival (OS) compared to best supportive
care (BSC) in Egyptian patients with advanced HCC.
Methods: This retrospective matched-cohort study was conducted at Tanta Cancer Center (TCC),
Egypt where 116 advanced HCC cases treated with tamoxifen were compared to TNM stage and
Child-Pugh class matched 116 HCC cases who received BSC.
Results: The median OS in the tamoxifen group was 9.3 months (95% conﬁdence interval [CI], 6.7–
11.9 months) compared to 8.7 months (95%CI, 6.8–10.6) in the BSC group (p= 0.758). With uni-
variate analyses, it was shown that absence of fatigue, Child-Pugh class A, single tumors, less
advanced tumors (T2), and absence of metastases (M0), had signiﬁcantly better OS than their coun-
terparts. Multivariate analysis showed that absence of fatigue, Child-Pugh class A and T2 tumors
were independent prognostic factors affecting OS. Tamoxifen produced partial response andical Oncology, National Can-
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2 A.A. Zeeneldin et al.clinical stabilization in one% and 16% of cases, respectively. The median PFS with tamoxifen was
7.2 months (95%CI, 5.2–9.5).
Conclusions: Tamoxifen did not show any OS advantage in Egyptian patients with advanced HCC.
Use of this drug is discouraged.
ª 2013 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
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Hepatocelluar carcinoma (HCC) is the most common form of
primary liver cancer [1]. Worldwide, liver cancer is the ﬁfth
and seventh most common cancer in men and women with
0.5 and 0.25 million new cases per year representing 7.9%
and 6.5% of the total cancers in males and females, respec-
tively. Most of HCC burden lies in developing countries.
The regions of high incidence include Eastern and South-
Eastern Asia, Middle and Western Africa. Worldwide, it is
the third most common cause of cancer death with mortality
to incidence ratio of 0.93 [2]. In Egypt, liver cancer ranks
fourth among all cancers representing 8% of total cancers
in both sexes. It is the second cause of cancer mortality rep-
resenting 10.5% of cancer deaths [2].
Risk factors for HCC are numerous and include hepatitis
B and C infections (HBV and HCV), cirrhosis, aﬂatoxins,
alcohol, smoking and male gender [3]. These risk factors
vary among countries, but chronic infections with HBV
and HCV are the most important precursors for HCC
development on a global scale. Together, HBV and HCV
infections account for over 80% of HCC cases
worldwide [4]. In Egypt, HCV is the main risk factor for
HCC where 71% of HCC cases are positive for anti-HCV
antibodies [5].
HCC has many treatment options. Surgery through resec-
tion or transplantation provides the best results in well-selected
candidates. If surgery is precluded, local nonsurgical therapies
like percutaneous ethanol injection or radiofrequency thermal
ablation can be used. Chemoembolization provides modest
survival advantage in patients with well-preserved liver func-
tion (Child-Pugh class A) and multi-nodular asymptomatic
tumors without vascular invasion [6]. Sorafenib, an oral mul-
ti-kinase inhibitor, is the only systemic therapy that showed
a clear survival beneﬁt in advanced HCC [7]. Systemic chemo-
therapy, immunotherapy, or anti-androgens did not show sur-
vival beneﬁt [6].
Epidemiological studies in humans suggest that long-term
use of oral contraceptives and anabolic androgenic steroids
can induce both benign and malignant hepatocellular tumors
[8]. Expression of sex hormone receptors, including estrogen
receptors (ER), can be detected in variable proportions of
HCC that range between 14% and 52% [9]. Earlier reviews
showed that the use of tamoxifen conferred a marginal survival
beneﬁt [10,11]. A large randomized controlled trial [12] as well
as two reviews [13,14] did not show survival beneﬁt with
tamoxifen use.
The aim of this study is to report the outcome of ad-
vanced HCC patients with the use of tamoxifen and to com-
pare that with an equal number of Child-Pugh class and
TNM stage-matched patients who received best supportive
care (BSC) at the same treating center and during the same
time interval.Methods
This retrospective matched-cohort study was conducted at
Tanta Cancer Center (TCC), Ministry of Health, Gharbiah
Governorate, Egypt. TCC is the largest cancer center in its
governorate and serves 4.2 million people constituting 5.7%
of the Egyptian population. Through TCC database, 116 cases
with advanced HCC and treated with tamoxifen 20 mg PO QD
were identiﬁed between the years 2003 and 2006 (Tamoxifen
group). Patients were considered eligible for tamoxifen if they
were ineligible for surgery, radiofrequency, ethanol injection or
trans-arterial chemoembolization. Patients who received other
systemic therapies (e.g. chemotherapy) or had an expected sur-
vival of less than three months were excluded. Through the
same database, we identiﬁed 116 advanced HCC patients
who received no speciﬁc treatment and were matched with
the tamoxifen group for both Child-Pugh class and TNM stage
(BSC group).
The following data were collected from the medical records:
age, sex, residence, occupation, history of hepatitis, smoking,
date of diagnosis, presence of cirrhosis, clinical presentation,
laboratory results (bilirubin, albumin, international normal-
ized ration (INR), alpha-fetoprotein (AFP)), Child-Pugh class,
site, size, number and stage of the primary tumor (T), regional
lymph node involvement (N), presence and site of metastases
(M), histological grade, treatments (tamoxifen vs. BSC), date
of therapy start and end, best overall response, date of progres-
sion and date and state of last contact.
The primary endpoint was overall survival (OS). Secondary
endpoints were progression free survival (PFS), response rate
(RR) and the impact of different clinico-pathological charac-
teristics as well as treatment on OS and PFS. OS was deﬁned
as the time (in months) from diagnosis to death. PFS was de-
ﬁned as the time (in months) from start of therapy until pro-
gression or death. Response was evaluated according to
WHO response criteria [15].
The study was carried out in compliance with the Helsinki
Declaration and was approved by the Institutional Review
board of Egyptian National Cancer Institute.
Statistical analyses
Data were analyzed using IBM SPSS Advanced Statistics
version 20.0 (SPSS Inc., Chicago, IL). The two treatment
groups were matched regarding Child-Pugh class and TNM
stage. McNemar test (McNemar-Bowker Test) was used to
examine the relation between qualitative variables. For quan-
titative data, comparison between the two matched groups
was done using paired t-test or Wilcoxon signed-ranks test.
Survival analysis was done using Kaplan–Meier method and
comparison between two survival curves was done using log-
rank test. Multivariate analysis was done using Cox-regression
analysis with forward conditional method for the signiﬁcant
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(OR) and its 95% conﬁdence interval (CI) were used for risk
estimation. A p-value 6 0.05 was considered signiﬁcant.
Results
In the two studied groups, Child-Pugh class A and B were
encountered in 29.3% and 70.7% of cases and TNM stages
II, III and IV were encountered in 6.3%, 75.7% and 18% of
cases, respectively. Both groups were largely comparable
regarding clinical and pathological characteristics (Table 1).
Patients in both groups were diagnosed in their late ﬁfties, pre-
dominately males, rural inhabitants and smokers. MostTable 1 Clinical characteristics of 232 HCC cases at TCC between
Characteristic Group BSC
Number
Demographics
Age (years) Mean ± SD 57.8 ± 10.9
Range 27–85
Sex Male 87
Female 29
Residence Rural 82
Urban 34
Occupation Employed 15
Unemployed 32
Farmer 42
House wife 27
Risk Factors
Smoking No 38
Yes 49
Viral hepatitis Positive 10
Unknown 106
Known hepatitis HCV 7
HBV 1
HBV and HCV 2
Cirrhosis Yes 87
No 29
AFP (ng/mL) Median 218
Range 0.6–2256.0
Tumor characteristics
Liver lobe site Right (Rt) 52
Left (Lt) 25
Rt& Lt 33
No. of lesions Single 66
Multiple 50
Known grade Low 52
High 11
Tumor size Median 7.0
Range 1.5–15.0
Tumor size group P5 cm 26
>5 cm 90
T stage 2 7
3 63
4 34
N stage 0 112
1 3
M stage 0 96
1 20
HCC: hepatocelluar carcinoma, TCC: Tanta Cancer Center, Egypt, BSC:
HB(C)V: hepatitis B (C)virus, T: tumor, N: regional lymph nodes, M: m
* No p value owing to the small number of cases across groups.patients in both groups presented with single tumors, involving
the right lobe, of a median largest diameter of 6.5 cm, and with
infrequent extra-hepatic extension. Nevertheless, more patients
in the Tamoxifen group than the BSC group had viral hepatitis
(24.1% vs. 8.6%, p= 0.002), elevated AFP (median, 500 vs.
218 ng/mL, p= 0.001), and tumors 65 cm (35.3% vs.
22.4%, p= 0.036). Abdominal pain, fatigue, ascites and
abdominal distension were the most common presentations
(Fig. 1). Fatigue was more common in the tamoxifen group
(91% vs. 82%; p= 0.052) and distension was more common
in the BSC group (42% vs. 54%; p= 0.034). Almost 63% of
cases were diagnosed histologically, 11% showed a classic
triphasic CT picture of HCC (arterial enhancement and rapid2003 and 2006.
Tamoxifen p
% Number %
59.8 ± 10.5
42–81 0.109
75.0 94 81.0
25.0 22 19.0 0.360
70.7 75 64.7
29.3 41 35.3 0.419
12.9 8 6.9
27.6 46 39.7
36.2 40 34.5
23.3 22 19 0.315
43.7 31 35.6
56.3 56 64.4 0.337
8.6 28 24.1
91.4 88 75.9 0.002
70.0 22 78.6
10.0 3 10.7
20.0 3 10.7 *
75.0 97 83.6
25.0 19 16.4 0.154
500
1.2–43504.0 0.001#
47.3 55 50.0
22.7 24 21.8
30.0 31 28.2 0.966
56.9 67 57.8
43.1 49 42.2 1.000
82.5 38 79.2
17.5 10 20.8 0.65
6.0
2.0–16.0 0.198
22.4 41 35.3
77.6 75 64.7 0.036
6.7 8 7.7
60.6 68 65.4
32.7 28 26.9 0.102
97.4 114 99.1
2.6 1 0.9 *
82.8 96 82.8
17.2 20 17.2 1.000
best supportive care, SD: standard deviation, AFP; alpha fetoprotein,
etastasis.
Figure 1 Clinical presentation in 232 HCC cases treated with
tamoxifen (Tam) or best supportive care (BSC). (*p< 0.05).
Figure 2 Overall survival in 116 HCC treated with tamoxifen
and 116 matched HCC cases who received best supportive care
(p= 0.76).
4 A.A. Zeeneldin et al.venous washout), and the rest of cases (26%) were diagnosed
based on elevated AFP together with the presence of cirrhosis
and hepatic focal lesions in liver ultrasound. In both groups,
low-grade tumors (grade 1 or 2) were more common than
high-grade tumors (grade 3 or 4). In patients presenting with
metastatic disease, bone was the most common site of metasta-
ses in both groups.
The median follow up period was 15.3 months (95%CI,
10.8–19.8). At the last documented visit, 139 patients were
dead; 73 in the BSC group and 66 in the tamoxifen group.
The median OS in the tamoxifen group was 9.3 months
(95%CI, 6.7–11.9) compared to 8.7 months (95%CI, 6.8–
10.6) in the BSC group (p= 0.758; Fig. 2). This is translated
into a hazard ratio of death in the tamoxifen arm of 0.95
(95%CI, 68–1.3). The 12-month OS rate in the tamoxifen
group was 41.2% compared to 40.7% in the BSC group.
The impact of various factors on OS was explored (Table 2).
Absence of fatigue, Child-Pugh class A, single lesions, T2 tu-
mors, absence of metastases (M0), all had signiﬁcantly better
OS than their counterparts. Survival of patients who received
tamoxifen was not signiﬁcantly different from that of patients
who received BSC only. Multivariate analysis showed thatabsence of fatigue, Child-Pugh class A and T2 tumors were
independent prognostic factors affecting OS (Table 3).
In the tamoxifen group, the median duration of tamoxifen
use was 4 months with an inter-quartile range (IQR) of 3–
8 months. Regarding the best overall response, only one pa-
tient achieved a documented partial response (Table 4). The
rest of patients were assessed on clinical basis with 16%
achieving clinical stabilization and 53% showing primary clin-
ical progression (Table 4). Thirty-four patients (29%) were
non-evaluable for response. The drug was generally tolerable
with clinical deterioration (e.g. deepening jaundice, increasing
ascites, elevated transaminases, worsening pains) being the
most common reason for drug withdrawal.
In the tamoxifen group, the median PFS was 7.2 months
(95%CI, 5.2–9.5; Fig. 3). The impacts on PFS of factors like
age, sex, residence, occupation, hepatitis, smoking, fatigue,
Child-Pugh class, number of lesions, AFP and TNM stage
were assessed. Only absence of fatigue and Child-Pugh class
A had signiﬁcantly higher PFS than the presence of fatigue
and Child-Pugh class B (p= 0.026 and <0.001, respectively).Discussion
HCC is a major health problem in Egypt ranking as the second
and sixth cancer in males and females representing 11.9% and
3.9% of all cancers, respectively. It is the second and sixth
cause of cancer mortality representing 14.4% and 5.7% in
males and females, respectively [2]. Many patients present with
advanced disease beyond curative surgery and effective local
and regional therapies [16].
Despite not a prospective randomized controlled trial
(RCT), our study included a good number of patients with ad-
vanced HCC distributed equally between those who received
tamoxifen and those who received BSC. They were derived
from the same treating center and during the same periods.
This minimized the effects of markedly different treatment pol-
icies between the two groups. They were matched regarding tu-
mor stage and Child-Pugh class, being very important
prognostic factors in advanced HCC. Our study reﬂects the
usual practice outside the setting of controlled clinical trials.
Patients included in this study are similar to patients with
HCC reported in large Egyptian series [16,17]. The median
age, predominance of males and rural inhabitance, farmers’
representation, the prevalence of HCV, HBV and combined
HBV and infection, clinical presentations, predominance of tu-
mors larger than 5 cm in diameter, lobar sites, predominance
of single lesions, were similar in the two studies. However,
our study included more Child-Pugh B patients (71%) than
the mentioned study (37%) and this is explained by the fact
that our patients were largely advanced cases that were ineligi-
ble for any surgical or other local and loco-regional interven-
tions compared to the mentioned study that included 60% of
patients who received surgery or other local and loco-regional
treatments. Thus, we believe that our HCC patients are repre-
sentative of Egyptian patients with advanced HCC.
Patients included in the current study largely resembled
those included in two large prospective randomized trials that
tested tamoxifen against BSC or no speciﬁc therapy in ad-
vanced HCC patients [12,18]. However, the median age was
6–10 years lower in our patients compared to Italian and
French patients. This reﬂects the lower life expectancy in
Table 2 Univariate analyses of factors affecting overall survival in 232 HCC cases treated at TCC.
Item Subgroup 12-month OS rate% (SE) 18-month OS rate% (SE) Median OS (95%CI) p Value
Age 658 years 42.9 (5.2) 32.2 (5.3) 10.2 (8.3–12.0)
>58 years 39.0 (5.4) 22.7 (5.2) 8.3 (6.5–10.2) 0.199
Sex Male 40.2 (4.3) 27.1 (4.1) 9.3 (7.5–11.1)
Female 45.2 (8.1) 31.7 (8.6) 9.2 (4.2–14.2) 0.682
Residence Rural 38.2 (4.4) 24.5 (4.3) 8.5 (7.0–10.0)
Urban 48.1 (7.1) 36.1 (7.5) 10.5 (4.8–16.2) 0.224
Fatigue No 90.9 (6.2) 90.9 (6.2) 30.1 (22.3–37.9)
Yes 33.9 (3.9) 18.9 (3.6) 8.1 (6.9–9.4) <0.001
Hepatitis Positive 32.5 (10.0) 32.5 (10.0) 7.2 (1.8–12.6)
Unknown 42.5 (4.1) 27.8 (4.0) 9.3 (7.3–11.3) 0.554
Occupation Farmers 35.4 (5.9) 25.6 (5.7) 7.7 (6.1–9.3)
Non-Farmers 44.8 (4.8) 29.3 (5.0) 9.6 (7.7–11.5) 0.558
Smoking Yes 41.8 (5.1) 31.6 (5.1) 9.6 (7.6–11.7)
No/Unknown 42.3 (5.6) 25.2 (5.5) 8.6 (6.5–10.7) 0.213
AFP (ng/mL) <200 53.2 (7.5) 32.0 (7.8) 13.3 (7.4–19.3)
P200 36.7 (4.3) 26.3 (4.3) 8.3 (6.9–9.7) 0.089
Child-Pugh A 93.0 (3.9) 86.0 (6.0) 30.1 (22.2–38.0)
B 22.7 (3.8) 8.2 (2.7) 7.1 (6.1–8.2) <0.001
No. of lesions Single 48.0 (5.0) 31.3 (5.1) 10.9 (8.0–13.8)
Multiple 31.0 (5.6) 22.5 (5.5) 7.4 (5.9–8.9) 0.013
T stage T2 83.9 (10.4) 67.1 (13.5) *
T3 40.4 (5.0) 24.4 (5.0) 8.6 (6.2–11.0)
T4 32.2 (6.7) 22.3 (6.2) 8.9 (6.7–11.1) 0.004
Regional LN No 40.5 (3.8) 27.9 (3.8) 9.1 (7.4–10.8)
Yes (0.0 (0.0) –** 9.4 (4.1–14.8) 0.850
Metastases No 43.8 (4.2) 29.4 (4.2) 10.2 (8.5–11.9)
Yes 26.9 (8.4) 20.2 (8.6) 7.4 (5.8–9.0) 0.035
Treatment BSC 40.7 (5.1) 29.3 (5.2) 8.7 (6.8–10.6)
Tamoxifen 41.2 (5.6) 26.2 (5.4) 9.3 (6.7–11.9) 0.758
HCC: hepatocelluar carcinoma, TCC: Tanta Cancer Center, Egypt, BSC: best supportive care. Median OS: median overall survival in months,
95%CI: 95% conﬁdence interval, SE: standard error, AFP; alpha fetoprotein.
* No median survival for T2 stage since more than half of patients are alive.
** Maximum follow up at 12 months.
Table 3 Multivariate analysis (Cox regression) of signiﬁcant variables affecting overall survival on univariate analysis.
B SE p Value OR 95%CI for OR
Child-Pugh class (B/A) 2.034 0.322 <0.001 7.7 4.1–14.4
Fatigue (yes/no) 1.434 0.467 0.002 4.2 1.7–10.5
T stage 0.013
T(3/2) 1.172 0.467 0.012 3.2 1.3–8.1
T(4/2) 0.792 0.476 0.096 2.2 0.9–5.6
No. of lesions (multiple/single) 0.466 0.243 0.051 1.6 0.99–2.6
Metastases (yes/no) 0.387 0.242 0.110 1.5 0.9–2.4
AFP (<200/P200) 0.234 0.219 0.322 1.3 0.8–1.9
B: Regression coefﬁcient, SE: standard error, OR: Odds ratio, CI: Conﬁdence interval, AFP: alpha fetoprotein.
Table 4 Best responses to tamoxifen in 116 patients with
advanced HCC treated with tamoxifen.
Response Number %
Radiological partial response 1 0.9
Stable clinical condition 19 16.4
Clinical progression 62 53.4
Unknown 34 29.3
Impact of tamoxifen on survival in HCC patients 5Egyptians (69 years in males and 73 years in females) com-
pared to Italian (77.9 years in males and 84 years in females)
and French people (78 years in males and 85 years in females)
[19]. It may also reﬂect earlier age at exposure to risk factors
including HCV, HBV, aﬂatoxins and insecticides [1]. Similar
to an Italian study [12], most of our patients had viral hepatitis
etiology mainly HCV. This is different from the French study
where alcoholic cirrhosis was the predominant risk factor [18].
All patients in the current study had evidence of cirrhosis
compared to 87%–92% in the mentioned studies. None of
Figure 3 Progression free survival 116 HCC patients treated
with tamoxifen.
6 A.A. Zeeneldin et al.our patients had Child-Pugh class C compared to 1%–15% in
the mentioned studies. None of the patients in the current
study received surgery, local or regional therapies compared
to 47% and 15% in the Italian and French studies, respectively
[12,18].
Similar to many RCTs [12,18,20–24] and meta-analyses
[12–14], we showed that tamoxifen did not confer any OS ben-
eﬁt in advanced HCC. However, the earlier claims of an OS
beneﬁt with the use of tamoxifen suggested by some RCTs
[25,26] and earlier meta-analyses [10,11] were criticized. These
RCTs [23,25,26] were mentioned to be of a low quality due to
methodological bias and random error of small sized trials and
thus they distorted earlier meta-analyses [10,11]. When high
quality RCTs [12,21,22,27] were included in the later meta-
analyses [12–14], the survival beneﬁt was no longer seen.
The median OS of tamoxifen and BSC groups in our study
(9.3 and 8.7 months, respectively) is lower than that of the
CLIP trial (15 and 16 months, respectively) [12]. In addition,
the one-year survival in the current study was lower (41.2%
vs. 56% for the tamoxifen and 40.7% vs. 57% for the control
group). This can be explained by the higher percentage of pa-
tients eligible for concurrent effective loco-regional therapies in
the CLIP trial (47%) compared to the current study (0%).
When patients receiving loco-regional therapies in the CLIP
trial were excluded, the median survival dropped signiﬁcantly
(6 and 5 months for tamoxifen and controls, respectively).
Similarly, the 1-year OS rate dropped to be 30% in the tamox-
ifen and 35% in the control groups. These ﬁgures are even low-
er than the corresponding ﬁgures in our current study. This
may be explained by the inclusion of Child-Pugh class C
(12.6%) in the CLIP trial compared to none in the current
study.
The ﬁgures for median OS and 1-year survival rates in the
current study are higher than the French RCT trial [18]. Pa-
tients in the French study were almost 10 years older than
those in the present study with alcoholic cirrhosis in their
majority compared to none in the current study. In addition,
that study included some patients with Child-Pugh class C
patients who were not represented in our study. Moreover,patients included in our study should have fulﬁlled an expected
life expectancy more than 3 months like the CLIP study [12].
This issue was not mentioned in the French study.
Similar to the French study [18], univariate analysis in the
current study showed that Child-Pugh class, tumor size and
numbers, presence of metastases were predictors of survival.
Also, we showed that fatigue was associated with survival both
in univariate and multivariate analyses in addition to Child-
Pugh class.
Similar to other investigators [21,23,28,29], we showed that
tumor responses to tamoxifen were very rare. The lack of
tamoxifen efﬁcacy could be due to either low expression of
wild-type ER (wER) [12] or to expression of mutated variants
(vER) that are inhibited by tamoxifen [30].
The impact of ER expression on beneﬁt from tamoxifen
was studied as a secondary analysis of a RCT and the results
were negative [23]. However, this approach was criticized. Pa-
tients were not prospectively selected or stratiﬁed according to
qualitative or quantitative hormonal receptors’ expression. Im-
mune-histochemical determinations were performed only on a
subgroup of 66/119 patients with adequate tissue specimen.
The prognosis of the patients enrolled in that study was dis-
mal, with a median survival of 44 days in the tamoxifen com-
pared to 41 days in the control group [9].
Tailoring anti-hormonal therapy according to the type of
ER was tried in a small trial where wER patients were treated
with tamoxifen and vER patients received megesterol acetate
with good responses in the tamoxifen group [31]. However,
these preliminary results still lack conﬁrmation in adequately
powered and designed RCTs that prospectively select patients
with wild-type ER and randomize them to receive tamoxifen
or no treatment. Also, adequately powered prospective phase
III trials assessing the efﬁcacy of tamoxifen in patients selected
or stratiﬁed (prospectively or retrospectively) for ER expres-
sion have never been conducted [9]. Increasing the dose of
tamoxifen did not prove to provide a better survival but rather
was more detrimental [14,24]. There were no signiﬁcant differ-
ences between tamoxifen and BSC arms within subgroups de-
ﬁned by prognostic variables such as stage, AFP level, portal
vein thrombosis, number of liver lesions, extent of liver
involvement, the preceding local or regional therapies [12]
and gender [14]. Thus, the use of tamoxifen in advanced
HCC is discouraged particularly with the availability of newly
approved drugs like Sorafenib [7].
In conclusion, this matched-cohort study conﬁrms the evi-
dence from previous RCTs and shows the lack of survival ben-
eﬁt with the use of tamoxifen in advanced HCC. Further use of
this drug is discouraged in these patients. Research to ﬁnd
more therapeutic targets and effective targeting agents is ea-
gerly needed in this disease with its grave prognosis.
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